

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of I VENTURES WES	2. Date of Event Requiring Statement (Month/Day/Year) 08/21/2008		3. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]				
(Last) (Fi 2500-1066 WEST H	irst) (Middle) ASTINGS STREET	06/21/2008		Issuer	f Reporting Person(s) to		5. If Amendment, Date Original Filed(Month/Day/Year)
(Str VANCOUVER, BC	^{reet)} V6E 3X 1			(Check Director Officer (give the below)	t all applicable) 10% Own tle Other (spe below)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (St	tate) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)			2. Amount of Sec Beneficially Owr (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Natur (Instr. 5	e of Indirect Beneficial Ownership)
Common Stock			926,819 ⁽¹⁾		Ι	See footnote (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable		3. Title and Amount of		4. Conversion	5. Ownership	6. Nature of Indirect Beneficial	
(Instr. 4)	and Expiration Date		Securities Underlying Derivative		or Exercise	Form of	Ownership	
	(Month/Day/Year)		Security		Price of	Derivative	(Instr. 5)	
			(Instr. 4)		Derivative	Security: Direct		
	Date	Expiration		A manual an Namahan af	Security	(D) or Indirect		
	Exercisable	Date T	Title	Amount or Number of Shares		(I)		
	Literensuoie	Date		Shares		(Instr. 5)		

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
VENTURES WEST CAPITAL LTD 2500-1066 WEST HASTINGS STREET VANCOUVER, BC V6E 3X 1		Х			

Signatures

Howard Riback, Chief Financial Officer	08/29/2008
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These securities include 264,810 shares that remain in escrow pending the achievement of certain milestones, as set forth in the Arrangement Agreement dated May 27,

(1) 2008 between Sonus Pharmaceuticals, Inc. and Oncogenex Technologies Inc., which is included as Exhibit 2.1 to the Issuer's Current Report on Form 8-K (File No. 0-21243) filed with the Securities and Exchange Commission on May 30, 2008, and incorporated herein by reference. If such milestones are not satisfied prior to August 21, 2014, all shares remaining in escrow will be cancelled.

845,643 shares of common stock are held of record by Ventures West 7 Limited Partnership, whose general partner is Ventures West 7 Management Ltd, an entity wholly owned by Ventures West Capital Ltd. and whose officers are similar to the officers of Ventures West Capital Ltd and 81,176 shares of common stock are held of record by

(2) Ventures West 7 U.S. Limited Partnership, whose manager is Ventures West 7 Management (International) Inc., an entity controlled by Ventures West Capital Ltd. and whose officers are similar to the officers of Ventures West Capital Ltd. All transactions involving securities held by Ventures West 7 Limited Partnership and Ventures West 7 U.S. Limited Partnership are completed in parallel.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.